The Role of Programmed Cell Death-1 (PD-1) and Its Ligands in Pediatric Cancer

被引:32
|
作者
van Dam, Laura S. [1 ]
de Zwart, Verena M. [1 ]
Meyer-Wentrup, Friederike A. G. [1 ]
机构
[1] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Pediat Hematol & Oncol, NL-3584 EA Utrecht, Netherlands
关键词
cancer immunotherapy; immune checkpoint blockade; PD-1/PD-L1; pediatric cancer; TUMOR-CELLS; POTENTIAL MECHANISM; B7-H1; EXPRESSION; B7; FAMILY; T-CELLS; RECEPTOR; BLOCKADE; SAFETY; ANTI-PD-1; ANTIBODY;
D O I
10.1002/pbc.25284
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Programmed cell death-1 (PD-1) and its ligands, PD-L1 and PD-L2 maintain self-tolerance and modulate physiological immune responses. Recently, targeting the PD-1/PD-L1 pathway with blocking antibodies has emerged as a potentially promising approach to treat advanced cancers in adult patients. Since tumor PD-L1 expression is currently considered the most important predictive biomarker for successful checkpoint blockade, we summarize expression data for the most common tumors of childhood. Additionally, we give an introduction into PD-1 function in the immune system to then focus on PD-1 mediated tumor immune escape. (C) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:190 / 197
页数:8
相关论文
共 50 条
  • [21] Targeting Programmed Cell Death-1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy
    Constantinidou, Anastasia
    Alifieris, Constantinos
    Trafalis, Dimitrios T.
    PHARMACOLOGY & THERAPEUTICS, 2019, 194 : 84 - 106
  • [22] Programmed Cell Death-1 Receptor (PD-1)-Mediated Regulation of Innate Lymphoid Cells
    Mallett, Grace
    Laurence, Arian
    Amarnath, Shoba
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (11)
  • [23] Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable
    Prasad, Vinay
    Kaestner, Victoria
    SEMINARS IN ONCOLOGY, 2017, 44 (02) : 132 - 135
  • [24] Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway
    Momtaz, Parisa
    Postow, Michael A.
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 : 357 - 365
  • [25] Programmed Death-1 Receptor (PD-1) as a Potential Prognosis Biomarker for Ovarian Cancer Patients
    Pawlowska, Anna
    Suszczyk, Dorota
    Tarkowski, Rafal
    Paduch, Roman
    Kotarski, Jan
    Wertel, Iwona
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 9691 - 9709
  • [26] Programmed death-1 (PD-1) polymorphism is associated with gastric cardia adenocarcinoma
    Tang, Weifeng
    Chen, Yu
    Chen, Shuchen
    Sun, Bin
    Gu, Haiyong
    Kang, Mingqiang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (05): : 8086 - 8093
  • [27] Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
    Guo, Liting
    Zhang, Haijun
    Chen, Baoan
    JOURNAL OF CANCER, 2017, 8 (03): : 410 - 416
  • [28] Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis
    Lazar-Molnar, Eszter
    Chen, Bing
    Sweeney, Kari A.
    Wang, Emilie J.
    Liu, Weijun
    Lin, Juan
    Porcelli, Steven A.
    Almo, Steven C.
    Nathenson, Stanley G.
    Jacobs, William R., Jr.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (30) : 13402 - 13407
  • [29] Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3
    Seko, Yoshinori
    Yagita, Hideo
    Okumura, Ko
    Azuma, Miyuki
    Nagai, Ryozo
    CARDIOVASCULAR RESEARCH, 2007, 75 (01) : 158 - 167
  • [30] The role of Programmed Death-1 (PD-1) in pulmonary M. tuberculosis infection: friend or foe?
    Lazar-Molnari, Eszter
    Cheni, Bing
    Almo, Steven
    Jacobs, William
    Nathenson, Stanley
    JOURNAL OF IMMUNOLOGY, 2010, 184